CTLA4 and melanoma: The currently approved dose of ipilimumab for patients with melanoma, however, achieves the target trough concentration of 20 mcg/mL, the level at which ipilimumab attains maximum CTLA-4 blockade, in only 30% of patients (68), suggesting that increasing the dose could yield improved clinical benefit, if toxicities can be managed.